UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cellular Senescence in Neurodegenerative Diseases

Frontiers in cellular neuroscience, 2020-02, Vol.14, p.16-16

2020

Volltextzugriff (PDF)

Signalling Pathways Implicated in Alzheimer′s Disease Neurodegeneration in Individuals with and without Down Syndrome

International journal of molecular sciences, 2020-09, Vol.21 (18), p.6906

2020

Volltextzugriff (PDF)

Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes

Neurobiology of disease, 2017-10, Vol.106, p.76-88

2017

Volltextzugriff (PDF)

Mouse Models of Down Syndrome as a Tool to Unravel the Causes of Mental Disabilities

Neural plasticity, 2012-01, Vol.2012 (2012), p.1-26

2012

Volltextzugriff (PDF)

Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome

PloS one, 2014-09, Vol.9 (9), p.e106572-e106572

2014

Volltextzugriff (PDF)

Nuclear Reorganization in Hippocampal Granule Cell Neurons from a Mouse Model of Down Syndrome: Changes in Chromatin Configuration, Nucleoli and Cajal Bodies

International journal of molecular sciences, 2021-01, Vol.22 (3), p.1259

2021

Volltextzugriff (PDF)

Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome

The Journal of neuroscience, 2013-02, Vol.33 (9), p.3953-3966

2013

Volltextzugriff (PDF)

Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene

Neurobiology of disease, 2018-02, Vol.110, p.206-217

2018

Volltextzugriff (PDF)

Oxidative-Stress-Associated Proteostasis Disturbances and Increased DNA Damage in the Hippocampal Granule Cells of the Ts65Dn Model of Down Syndrome

Antioxidants, 2022-12, Vol.11 (12), p.2438

2022

Volltextzugriff (PDF)

Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome

Journal of pineal research, 2013-04, Vol.54 (3), p.346-358

2013

Volltextzugriff (PDF)

Early postnatal oleic acid administration enhances synaptic development and cognitive abilities in the Ts65Dn mouse model of Down syndrome

Nutritional neuroscience, 2022-07, Vol.25 (7), p.1400-1412

2022

Volltextzugriff (PDF)

Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome

Progress in brain research, 2020, Vol.251, p.245

2020

Volltextzugriff (PDF)

Melatonin Enhances the Usefulness of Ionizing Radiation: Involving the Regulation of Different Steps of the Angiogenic Process

Frontiers in physiology, 2019-07, Vol.10, p.879-879

2019

Volltextzugriff (PDF)

Apoptosis in Down’s syndrome: lessons from studies of human and mouse models

Apoptosis (London), 2013-02, Vol.18 (2), p.121-134

2013

Volltextzugriff (PDF)

Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials

Antioxidants, 2020-08, Vol.9 (8), p.692

2020

Volltextzugriff (PDF)

Effects of chronic administration of SGS-111 during adulthood and during the pre- and post-natal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome

Behavioural brain research, 2008-04, Vol.188 (2), p.355-367

2008

Volltextzugriff (PDF)

The Ts65Dn mouse model of Down syndrome shows reduced expression of the Bcl-X L antiapoptotic protein in the hippocampus not accompanied by changes in molecular or cellular markers of cell death

International journal of developmental neuroscience, 2011-11, Vol.29 (7), p.711-716

2011

Volltextzugriff (PDF)

Prenatal Administration of Oleic Acid or Linolenic Acid Reduces Neuromorphological and Cognitive Alterations in Ts65dn Down Syndrome Mice

The Journal of nutrition, 2020-06, Vol.150 (6), p.1631-1643

2020

Volltextzugriff (PDF)

Prenatal, but not Postnatal, Curcumin Administration Rescues Neuromorphological and Cognitive Alterations in Ts65Dn Down Syndrome Mice

The Journal of nutrition, 2020-09, Vol.150 (9), p.2478-2489

2020

Volltextzugriff (PDF)

Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders

Current medicinal chemistry, 2017-11, Vol.24 (35)

2017

Volltextzugriff (PDF)

Usefulness of melatonin as complementary to chemotherapeutic agents at different stages of the angiogenic process

Scientific reports, 2020-03, Vol.10 (1), p.4790, Article 4790

2020

Volltextzugriff (PDF)

Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice

Brain, behavior, and immunity, 2018-10, Vol.73, p.235-251

2018

Volltextzugriff (PDF)

Signalling Pathways Implicated in Alzheimer's Disease Neurodegeneration in Individuals with and without Down Syndrome

International journal of molecular sciences, 2020-09, Vol.21 (18)

2020

Volltextzugriff (PDF)

Chronic Melatonin Administration Reduced Oxidative Damage and Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome

Neurochemical research, 2016-11, Vol.41 (11), p.2904-2913

2016

Volltextzugriff (PDF)

Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the Ts65Dn mouse model of Down syndrome

Behavioural brain research, 2017-09, Vol.334, p.142-154

2017

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(68)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Cellular Senescence in Neurodegenerative Diseases

Signalling Pathways Implicated in Alzheimer′s Disease Neurodegeneration in Individuals with and without Down Syndrome

Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes

Mouse Models of Down Syndrome as a Tool to Unravel the Causes of Mental Disabilities

Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome

Nuclear Reorganization in Hippocampal Granule Cell Neurons from a Mouse Model of Down Syndrome: Changes in Chromatin Configuration, Nucleoli and Cajal Bodies

Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome

Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene

Oxidative-Stress-Associated Proteostasis Disturbances and Increased DNA Damage in the Hippocampal Granule Cells of the Ts65Dn Model of Down Syndrome

Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome

Early postnatal oleic acid administration enhances synaptic development and cognitive abilities in the Ts65Dn mouse model of Down syndrome

Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome

Melatonin Enhances the Usefulness of Ionizing Radiation: Involving the Regulation of Different Steps of the Angiogenic Process

Apoptosis in Down’s syndrome: lessons from studies of human and mouse models

Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials

Effects of chronic administration of SGS-111 during adulthood and during the pre- and post-natal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome

The Ts65Dn mouse model of Down syndrome shows reduced expression of the Bcl-X L antiapoptotic protein in the hippocampus not accompanied by changes in molecular or cellular markers of cell death

Prenatal Administration of Oleic Acid or Linolenic Acid Reduces Neuromorphological and Cognitive Alterations in Ts65dn Down Syndrome Mice

Prenatal, but not Postnatal, Curcumin Administration Rescues Neuromorphological and Cognitive Alterations in Ts65Dn Down Syndrome Mice

Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders

Usefulness of melatonin as complementary to chemotherapeutic agents at different stages of the angiogenic process

Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice

Signalling Pathways Implicated in Alzheimer's Disease Neurodegeneration in Individuals with and without Down Syndrome

Chronic Melatonin Administration Reduced Oxidative Damage and Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome

Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the Ts65Dn mouse model of Down syndrome

Suchergebnisse filtern